Abstracts

CHARACTERIZING HIV EXPRESSION IN VIVO

HIV proviruses persist in vivo in latent and transcriptionally active forms. Little is known regarding the fraction of infected cells in blood and in tissues that are quiescent versus those that actively express HIV RNA in either ART treated or untreated individuals, although it is known that the majority of proviruses are defective for viral…

IMMUNE-BASED INTERVENTIONS TARGETING INFLAMMATION AND VIRAL PERSISTENCE

Antiretroviral therapy (ART) suppresses viral replication in HIV-infected individuals, but does not eliminate an extremely durable reservoir of latently infected cells that is established early after infection. Consequently, discontinuation of ART typically leads to rapid rebound of plasma viremia Understanding the phenotype and location of latently infected cells represents a critical challenge in designing a…

THERAPEUTIC VACCINATION FOR HIV/SIV: WHAT WILL IT TAKE FOR CURE?

Current understanding of the residual virus remaining in HIV-infected subjects on optimally effective antiretroviral therapy (ART) suggests that functional HIV cure will require either viral eradication or substantial viral reservoir reduction combined with potent, long-term anti-viral immunity such that any viral reactivation that occurs after ART cessation is eliminated or stringently controlled over a lifetime.…

MDR-TB EPIDEMIOLOGY AND TRANSMISSION DYNAMICS

Drug-resistant tuberculosis (TB) is a global public health crisis, with 480,000 cases occurring annually and 190,000 dying of this disease. Extensively drug-resistant (XDR) TB involves resistance to the most potent first-line and second-line drugs to treat TB and has been reported from over 100 countries. Although the End TB Strategy calls for universal access to…

EMERGING TREATMENT ISSUES IN MDR-TB

The treatment of Drug Resistant TB involved the use of long regimens with poor efficacy and a high drug related adverse event rate. Internationally, a successful outcome of treatment of who are diagnosed DR TB was 50%. Many patients started on treatment are loss to the program in part due to the side effects. In…

NEW DIAGNOSTIC TECHNOLOGIES FOR MDR-TB

The diagnostic gap remains greater for TB than for any other infectious disease; more than 80% of patients with multi-drug resistance remain undiagnosed or unreported. Many years of lab strengthening efforts have shown that scaling up BSL3 capacity for culture drug susceptibility testing will not be a feasible, or sustainable solution. Remarkable progress has been…

THE CHALLENGES OF TREATING MDR-TB IN CHILDREN

The paucibacillary nature of tuberculosis (TB) and the difficulty in obtaining samples for bacteriology in children are important barriers to diagnosis of paediatric MDR-TB. Although 25,000 children were estimated to have developed MDR-TB in 2014, only a small number are reported in the literature as appropriately treated from 1990-2014. Early and appropriate diagnosis is a…

VAGINAL MICROBIOME AND SUSCEPTIBILITY TO HIV

Several prospective studies published over nearly two decades have explored the relationship between vaginal dysbiosis and women’s risk of HIV acquisition. These studies have typically used Gram stain scoring based on bacterial morphotypes to characterize vaginal microbiota in categories including normal (scores 0-3), intermediate vaginal microbiota (scores 4-6), and bacterial vaginosis (BV; scores 7-10). Together,…